Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity is a research paper published in Journal for ImmunoTherapy of Cancer (2024). On theSindex it has a DataRank of 0.416. It has been cited 15 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.416
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH
Grant: AI125640
NIH
Grant: AI150597
NIH
Grant: AI175498
NIH
Grant: CA231277
NIH
Grant: S10OD030282
NCI NIH HHS
Grant: R21 CA231277
NIAID NIH HHS
Grant: R01 AI150597
NIAID NIH HHS
Grant: R01 AI175498
NIGMS NIH HHS
Grant: T32 GM145440
NIAID NIH HHS
Grant: R01 AI125640
National Institutes of Health
Grant: 5R01AI175498-03
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events
National Institutes of Health
Grant: 5R01AI125640-09
Novel mechanisms regulating PD-1 signaling and function
National Institutes of Health
Grant: 1S10OD030282-01A1
Five-laser Aurora spectral flow cytometer
National Institutes of Health
Grant: 1R21CA231277-01A1
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade
National Institutes of Health
Grant: 5R01AI150597-04
PAG is a novel target in immunotherapy
FWCI
2.67
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals